Breaking News

Tweet TWEET

Genomic Health to Announce Fourth Quarter and Year-End 2012 Financial Results and Host Conference Call on Wednesday, February 6,

Genomic Health to Announce Fourth Quarter and Year-End 2012 Financial Results
           and Host Conference Call on Wednesday, February 6, 2013

PR Newswire

REDWOOD CITY, Calif., Jan. 30, 2013

REDWOOD CITY, Calif., Jan. 30, 2013 /PRNewswire/ --Genomic Health,
Inc.(Nasdaq: GHDX) today announced that the company will host a conference
call and webcast onWednesday, February 6 at4:30 p.m. Eastern Timeto discuss
its fourth quarter and year-end 2012 financial results. The call and webcast
will follow the release of the fourth quarter financial results after market
close.

Conference Call Details
To access the live conference call on February 6 at 4:30 p.m. Eastern Time via
phone, please dial (877) 303-7208 from the United States and Canada or +1(224)
357-2389 internationally. Please dial in approximately ten minutes prior to
the start of the call.

To access the live and subsequently archived webcast of the conference call,
go to theInvestor Relationssection of the company's website at
http://investor.genomichealth.com. Please connect to the website at least 15
minutes prior to the call to allow for any software download that may be
necessary.

AboutGenomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that
provides actionable genomic information to personalize cancer treatment
decisions. The company's lead product, the Oncotype DX^® breast cancer test,
has been shown to predict the likelihood of chemotherapy benefit as well as
recurrence in invasive breast cancer and has been shown to predict the
likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to
this widely adopted test, Genomic Health provides the Oncotype DX Colon Cancer
test, the first multi-gene expression test developed for the assessment of
risk of recurrence in patients with stage II and stage III disease. As of
September 30, 2012, more than 10,000 physicians in over 65 countries had
ordered more than 320,000 Oncotype DX tests. Genomic Health has a robust
pipeline focused on developing tests to optimize the treatment of prostate and
renal cell cancers, as well as additional treatment decisions in breast and
colon cancers. The company is based in Redwood City, California with European
headquarters in Geneva, Switzerland. For more information, please visit,
www.GenomicHealth.com. To learn more about the Oncotype DX tests, visit:
www.OncotypeDX.com and www.mybreastcancertreatment.org.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the attributes and focus of the company's product pipeline; the
applicability of clinical study results to actual outcomes; the potential
economic benefits associated with the company's tests; the ability of the
company to develop additional tests in the future; the demand for the
company's tests; the ability of any potential tests the company may develop to
optimize cancer treatment and the Company's ability to launch new tests in new
markets and expand internationally. Forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ materially,
and reported results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not limited to:
the risks and uncertainties associated with the regulation of the company's
tests; the results of clinical studies; the applicability of clinical study
results to actual outcomes; our ability to develop and commercialize new
tests; unanticipated costs or delays in research and development efforts; our
ability to obtain capital when needed and the other risks set forth in the
company's filings with theSecurities and Exchange Commission, including the
risks set forth in the company's Quarterly Report on Form 10-Q for the quarter
ended September 30, 2012. These forward-looking statements speak only as of
the date hereof. Genomic Health disclaims any obligation to update these
forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and
DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their respective
owners. 

Contacts:
Investors:
Dean Schorno
Genomic Health
650-569-2281
investors@genomichealth.com

Media:
Emily Faucette
Genomic Health
650-569-2215
media@genomichealth.com

SOURCE Genomic Health, Inc.

Website: http://www.genomichealth.com
 
Press spacebar to pause and continue. Press esc to stop.